A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease

Thomas E. Rohan, Abdissa Negassa, Rowan T. Chlebowski, Clementina D. Ceria-Ulep, Barbara B. Cochrane, Dorothy S. Lane, Mindy S. Ginsberg, Sylvia Wassertheil-Smoller, David L. Page

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Experimental evidence provides strong support for anti-carcinogenic effects of calcium and vitamin D with respect to breast cancer. Observational epidemiologic data also provide some support for inverse associations with risk. We tested the effect of calcium plus vitamin D supplementation on risk of benign proliferative breast disease, a condition which is associated with increased risk of breast cancer. We used the Women's Health Initiative randomized controlled trial. The 36,282 participants were randomized either to 500 mg of elemental calcium as calcium carbonate plus 200 IU of vitamin D 3 (GlaxoSmithKline) twice daily (n = 18,176) or to placebo (n = 18,106). Regular mammograms and clinical breast exams were performed. We identified women who had had a biopsy for benign breast disease and subjected histologic sections from the biopsies to standardized review. After an average follow-up period of 6.8 years, 915 incident cases of benign proliferative breast disease had been ascertained, with 450 in the intervention group and 465 in the placebo group. Calcium plus vitamin D supplementation was not associated with altered risk of benign proliferative breast disease overall (hazard ratio = 0.99, 95% confidence interval = 0.86-1.13), or by histologic subtype. Risk varied significantly by levels of age at baseline, but not by levels of other variables. Daily use of 1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D3 for almost 7 years by postmenopausal women did not alter the overall risk of benign proliferative breast disease.

Original languageEnglish (US)
Pages (from-to)339-350
Number of pages12
JournalBreast Cancer Research and Treatment
Volume116
Issue number2
DOIs
StatePublished - Jul 2009

Fingerprint

Breast Diseases
Vitamin D
Randomized Controlled Trials
Calcium
Calcium Carbonate
Cholecalciferol
Placebos
Anticarcinogenic Agents
Breast Neoplasms
Biopsy
Women's Health
Breast
Confidence Intervals

Keywords

  • Benign proliferative breast disease
  • Calcium
  • Vitamin D

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. / Rohan, Thomas E.; Negassa, Abdissa; Chlebowski, Rowan T.; Ceria-Ulep, Clementina D.; Cochrane, Barbara B.; Lane, Dorothy S.; Ginsberg, Mindy S.; Wassertheil-Smoller, Sylvia; Page, David L.

In: Breast Cancer Research and Treatment, Vol. 116, No. 2, 07.2009, p. 339-350.

Research output: Contribution to journalArticle

Rohan, Thomas E. ; Negassa, Abdissa ; Chlebowski, Rowan T. ; Ceria-Ulep, Clementina D. ; Cochrane, Barbara B. ; Lane, Dorothy S. ; Ginsberg, Mindy S. ; Wassertheil-Smoller, Sylvia ; Page, David L. / A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. In: Breast Cancer Research and Treatment. 2009 ; Vol. 116, No. 2. pp. 339-350.
@article{d15e663aeb9c412bba1ff97a5520761e,
title = "A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease",
abstract = "Experimental evidence provides strong support for anti-carcinogenic effects of calcium and vitamin D with respect to breast cancer. Observational epidemiologic data also provide some support for inverse associations with risk. We tested the effect of calcium plus vitamin D supplementation on risk of benign proliferative breast disease, a condition which is associated with increased risk of breast cancer. We used the Women's Health Initiative randomized controlled trial. The 36,282 participants were randomized either to 500 mg of elemental calcium as calcium carbonate plus 200 IU of vitamin D 3 (GlaxoSmithKline) twice daily (n = 18,176) or to placebo (n = 18,106). Regular mammograms and clinical breast exams were performed. We identified women who had had a biopsy for benign breast disease and subjected histologic sections from the biopsies to standardized review. After an average follow-up period of 6.8 years, 915 incident cases of benign proliferative breast disease had been ascertained, with 450 in the intervention group and 465 in the placebo group. Calcium plus vitamin D supplementation was not associated with altered risk of benign proliferative breast disease overall (hazard ratio = 0.99, 95{\%} confidence interval = 0.86-1.13), or by histologic subtype. Risk varied significantly by levels of age at baseline, but not by levels of other variables. Daily use of 1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D3 for almost 7 years by postmenopausal women did not alter the overall risk of benign proliferative breast disease.",
keywords = "Benign proliferative breast disease, Calcium, Vitamin D",
author = "Rohan, {Thomas E.} and Abdissa Negassa and Chlebowski, {Rowan T.} and Ceria-Ulep, {Clementina D.} and Cochrane, {Barbara B.} and Lane, {Dorothy S.} and Ginsberg, {Mindy S.} and Sylvia Wassertheil-Smoller and Page, {David L.}",
year = "2009",
month = "7",
doi = "10.1007/s10549-008-0213-0",
language = "English (US)",
volume = "116",
pages = "339--350",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease

AU - Rohan, Thomas E.

AU - Negassa, Abdissa

AU - Chlebowski, Rowan T.

AU - Ceria-Ulep, Clementina D.

AU - Cochrane, Barbara B.

AU - Lane, Dorothy S.

AU - Ginsberg, Mindy S.

AU - Wassertheil-Smoller, Sylvia

AU - Page, David L.

PY - 2009/7

Y1 - 2009/7

N2 - Experimental evidence provides strong support for anti-carcinogenic effects of calcium and vitamin D with respect to breast cancer. Observational epidemiologic data also provide some support for inverse associations with risk. We tested the effect of calcium plus vitamin D supplementation on risk of benign proliferative breast disease, a condition which is associated with increased risk of breast cancer. We used the Women's Health Initiative randomized controlled trial. The 36,282 participants were randomized either to 500 mg of elemental calcium as calcium carbonate plus 200 IU of vitamin D 3 (GlaxoSmithKline) twice daily (n = 18,176) or to placebo (n = 18,106). Regular mammograms and clinical breast exams were performed. We identified women who had had a biopsy for benign breast disease and subjected histologic sections from the biopsies to standardized review. After an average follow-up period of 6.8 years, 915 incident cases of benign proliferative breast disease had been ascertained, with 450 in the intervention group and 465 in the placebo group. Calcium plus vitamin D supplementation was not associated with altered risk of benign proliferative breast disease overall (hazard ratio = 0.99, 95% confidence interval = 0.86-1.13), or by histologic subtype. Risk varied significantly by levels of age at baseline, but not by levels of other variables. Daily use of 1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D3 for almost 7 years by postmenopausal women did not alter the overall risk of benign proliferative breast disease.

AB - Experimental evidence provides strong support for anti-carcinogenic effects of calcium and vitamin D with respect to breast cancer. Observational epidemiologic data also provide some support for inverse associations with risk. We tested the effect of calcium plus vitamin D supplementation on risk of benign proliferative breast disease, a condition which is associated with increased risk of breast cancer. We used the Women's Health Initiative randomized controlled trial. The 36,282 participants were randomized either to 500 mg of elemental calcium as calcium carbonate plus 200 IU of vitamin D 3 (GlaxoSmithKline) twice daily (n = 18,176) or to placebo (n = 18,106). Regular mammograms and clinical breast exams were performed. We identified women who had had a biopsy for benign breast disease and subjected histologic sections from the biopsies to standardized review. After an average follow-up period of 6.8 years, 915 incident cases of benign proliferative breast disease had been ascertained, with 450 in the intervention group and 465 in the placebo group. Calcium plus vitamin D supplementation was not associated with altered risk of benign proliferative breast disease overall (hazard ratio = 0.99, 95% confidence interval = 0.86-1.13), or by histologic subtype. Risk varied significantly by levels of age at baseline, but not by levels of other variables. Daily use of 1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D3 for almost 7 years by postmenopausal women did not alter the overall risk of benign proliferative breast disease.

KW - Benign proliferative breast disease

KW - Calcium

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=67649236554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649236554&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-0213-0

DO - 10.1007/s10549-008-0213-0

M3 - Article

VL - 116

SP - 339

EP - 350

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -